How Long Before Allergy Shots Work? The Honest Guide to the Waiting Period

Yes, seeing no improvement for the first 6 months is clinically expected for many patients and is not a sign of treatment failure. The build-up phase — 8 to 28 weeks of escalating doses — is primarily an immune priming period where biological changes are occurring at the cellular level but have not yet crossed the threshold that produces subjective symptom relief. IgG4 blocking antibodies begin rising at 1 to 3 months but need 3 to 6 months or more to reach clinically meaningful concentrations. The AAAAI/ACAAI Practice Parameter recommends formal non-responder evaluation only after 1 full year of maintenance dosing, explicitly recognizing that 6 months without improvement is within normal clinical range.

After 12 months of maintenance dosing without improvement, your allergist should conduct a structured non-responder evaluation covering several key areas. First, they verify whether the target maintenance dose was actually achieved — patients dose-limited by local or systemic reactions may be receiving subtherapeutic allergen concentrations. Second, the allergen formulation is reviewed for accuracy — component-resolved diagnostics can identify whether the extract targets your clinically significant IgE sensitivities or whether a major trigger was missed. Third, attendance records are reviewed to identify dose-reset gaps. Fourth, the diagnosis is reconsidered — some patients with apparent allergy symptoms have non-IgE mechanisms that do not respond to immunotherapy. Fifth, concurrent medications are reviewed for masking effects. Based on this evaluation, your allergist may recommend formulation adjustment, dose escalation, or, if all factors have been optimized, discontinuation.

Managing the pre-result period psychologically is as important as managing it medically. Three practical strategies help patients persist through it. First, keep a weekly symptom diary — patients who track objectively often detect subtle improvement they would otherwise miss, and having a written record prevents the brain from anchoring only on today's symptom level. Second, use the AAAAI-recommended concurrent medications during build-up (antihistamines, nasal corticosteroids) without guilt — managing symptoms concurrently does not undermine immunotherapy and makes the waiting period livable. Third, know your benchmark: at 12 months of maintenance dosing, you have clinical grounds to request a formal reassessment. Before that point, staying the course is the evidence-based recommendation.

Some temporary worsening is reported during the build-up phase and is considered clinically normal. Local injection site reactions — redness, swelling, itching — are very common (26 to 86 percent of patients) and peak during the early build-up escalations. Mild fatigue on injection days is frequently reported. A transient rise in allergen-specific IgE may occur early in treatment before it eventually declines, potentially temporarily heightening sensitivity. These experiences should all be reported to your allergist, who can advise on dose adjustments and symptomatic management. Importantly, large local reactions (greater than golf ball size or persisting more than 24 hours) should always be reported, as they may indicate dose adjustment is needed. Systemic symptoms — hives, throat tightness, difficulty breathing — after an injection require immediate allergist or emergency care evaluation.

The 77 percent dropout rate before completing 3 years of allergy shots concentrates in the pre-result period, and the drivers are well documented. Vaswani et al. (Ann Allergy Asthma Immunol, 2015) surveyed 555 patients who discontinued and found 40 percent cited inadequate insurance coverage and copays as the primary reason, 15 percent cited inconvenience of travel and appointments, 8 percent cited relocation, and 4 percent cited perceived lack of efficacy. Crucially, stopping during the pre-result period — before 12 months of maintenance dosing — yields essentially no durable benefit, meaning patients invest months of clinic visits and expense without achieving any lasting return. Understanding this dynamic before starting treatment is essential for making a realistic commitment decision.